ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)
Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –
ImmuCell net income
Net income is the profit left for shareholders after every expense, interest and tax.
ImmuCell's net income for the twelve months ending Jun 30, 2026 was $787.37K, down 55.3% year over year. For fiscal 2025 it was -$1.04M. The highest annual figure on record is $1.21M in fiscal 2015.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.04M | – |
| FY2024 | Dec 31, 2024 | -$2.16M | – |
| FY2023 | Dec 31, 2023 | -$5.77M | – |
| FY2022 | Dec 31, 2022 | -$2.49M | – |
| FY2021 | Dec 31, 2021 | -$78.29K | – |
| FY2020 | Dec 31, 2020 | -$1.02M | – |
| FY2019 | Dec 31, 2019 | -$1.30M | – |
| FY2018 | Dec 31, 2018 | -$2.32M | – |
| FY2017 | Dec 31, 2017 | -$168.15K | -133.1% |
| FY2016 | Dec 31, 2016 | $508.45K | -58.1% |
| FY2015 | Dec 31, 2015 | $1.21M | – |
| FY2014 | Dec 31, 2014 | -$167.16K | -242.4% |
| FY2013 | Dec 31, 2013 | $117.40K | +31.2% |
| FY2012 | Dec 31, 2012 | $89.51K | – |
| FY2011 | Dec 31, 2011 | -$409.51K | – |
| FY2010 | Dec 31, 2010 | -$384.68K | – |
| FY2009 | Dec 31, 2009 | -$216.49K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.83M | +265.6% |
| Q1 FY2026 | Mar 31, 2026 | $1.94M | +34.2% |
| Q4 FY2025 | Dec 31, 2025 | -$2.85M | -653.7% |
| Q3 FY2025 | Sep 30, 2025 | -$139.75K | – |
| Q2 FY2025 | Jun 30, 2025 | $501.88K | – |
| Q1 FY2025 | Mar 31, 2025 | $1.45M | – |
| Q4 FY2024 | Dec 31, 2024 | $514.56K | – |
| Q3 FY2024 | Sep 30, 2024 | -$701.69K | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$437.87K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$940.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.32M | -551.0% |
| Q4 FY2022 | Dec 31, 2022 | -$1.67M | -2349.8% |
| Q3 FY2022 | Sep 30, 2022 | -$655.08K | -543.3% |
| Q2 FY2022 | Jun 30, 2022 | -$684.15K | -584.8% |
| Q1 FY2022 | Mar 31, 2022 | $513.29K | – |
| Q4 FY2021 | Dec 31, 2021 | $74.13K | -60.7% |
| Q3 FY2021 | Sep 30, 2021 | $147.76K | – |
| Q2 FY2021 | Jun 30, 2021 | $141.11K | – |
| Q1 FY2021 | Mar 31, 2021 | -$441.30K | – |
| Q4 FY2020 | Dec 31, 2020 | $188.83K | – |
| Q3 FY2020 | Sep 30, 2020 | -$322.89K | – |
| Q2 FY2020 | Jun 30, 2020 | -$765.79K | – |
| Q1 FY2020 | Mar 31, 2020 | -$122.27K | -184.6% |
| Q4 FY2019 | Dec 31, 2019 | -$310.45K | – |
| Q3 FY2019 | Sep 30, 2019 | -$502.54K | – |
| Q2 FY2019 | Jun 30, 2019 | -$627.16K | – |
| Q1 FY2019 | Mar 31, 2019 | $144.56K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.05M | – |
| Q3 FY2018 | Sep 30, 2018 | -$249.96K | – |
| Q2 FY2018 | Jun 30, 2018 | -$798.36K | – |
| Q1 FY2018 | Mar 31, 2018 | -$221.12K | -137.8% |
| Q4 FY2017 | Dec 31, 2017 | -$194.66K | -742.7% |
| Q3 FY2017 | Sep 30, 2017 | -$339.35K | -1073.2% |
| Q2 FY2017 | Jun 30, 2017 | -$218.39K | – |
| Q1 FY2017 | Mar 31, 2017 | $584.24K | – |
| Q4 FY2016 | Dec 31, 2016 | $30.29K | – |
| Q3 FY2016 | Sep 30, 2016 | $34.87K | – |
See a number that looks wrong?